US 2016/0106679 A1 · TABLET WITH INCREASED DRUG LOAD OF ODANACATIB

Abstract

The present invention relates to pharmaceutical tablets comprising amorphous compound I in the form of its free base or pharmaceutically acceptable salts of compound I.

Claims17

Dependent claims

A tablet comprising a pharmacologically effective amount of amorphous odanacatib free base of

Compound 1 in an amount from 10% to 25% in weight of active moiety based on a total weight of the tablet.

Dependencies are inferred from the claim text.

Facts

Application

14/890,271Filed 16 May 2014

Priority

EP 13168095.116 May 2013

Published

21 Apr 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 9/2054
Polysaccharides, e.g. alginate, gums; Cyclodextrin: cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
A61K 9/146
Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried,…: with…
A61K 9/2009
Excipients; Inactive ingredients: inorganic compounds
A61K 9/2018
Organic compounds, e.g. phospholipids, fats: sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

The present invention relates to pharmaceutical tablets comprising amorphous compound I in the form of its free base or pharmaceutically acceptable salts of compound I.

Claims17

Dependent claims

A tablet comprising a pharmacologically effective amount of amorphous odanacatib free base of

Compound 1 in an amount from 10% to 25% in weight of active moiety based on a total weight of the tablet.

Dependencies are inferred from the claim text.

Tablet with increased drug load of odanacatib

Life of this patent

Abstract

Claims17

Tablet with increased drug load of odanacatib

Life of this patent

Abstract

Claims17